0.1715
Schlusskurs vom Vortag:
$0.20
Offen:
$0.1928
24-Stunden-Volumen:
6.75M
Relative Volume:
0.65
Marktkapitalisierung:
$23.25M
Einnahmen:
$1.73M
Nettoeinkommen (Verlust:
$-23.50M
KGV:
-0.7853
EPS:
-0.2184
Netto-Cashflow:
$-19.37M
1W Leistung:
-11.14%
1M Leistung:
-15.39%
6M Leistung:
-72.57%
1J Leistung:
-68.28%
VolitionRX Ltd Stock (VNRX) Company Profile
Firmenname
VolitionRX Ltd
Sektor
Branche
Telefon
646 650 1351
Adresse
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
VNRX
VolitionRX Ltd
|
0.1715 | 23.25M | 1.73M | -23.50M | -19.37M | -0.2184 |
|
TMO
Thermo Fisher Scientific Inc
|
491.46 | 182.57B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
191.12 | 135.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
569.55 | 45.24B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
115.48 | 32.63B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
304.24 | 29.85B | 3.17B | 642.63M | 516.49M | 10.77 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Eingeleitet | Maxim Group | Buy |
| 2018-05-14 | Bestätigt | The Benchmark Company | Buy |
| 2016-09-07 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-02-01 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten
VolitionRx Earnings Call: Breakthroughs Amid Funding Strain - TipRanks
VolitionRx Limited (VNRX) stock price, news, quote and history - Yahoo Finance UK
VolitionRX (VNRX) FY2025 Earnings: Q4 EPS and Revenue Not Disclo - GuruFocus
VolitionRX Is Maintained at Buy by HC Wainwright & Co. - Moomoo
VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript - Insider Monkey
VolitionRX Q4 Earnings Call Highlights - Defense World
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
VolitionRx: Robust Revenue Growth and Promising Capture-Seq Data Support Buy Rating Despite Dilution-Driven Target Cut - TipRanks
VolitionRX (VNRX) Sees Target Price Cut Despite Maintained Buy R - GuruFocus
VolitionRx Limited (VNRX) 8-K SEC Filing March 31, 2026: Company Details, Address, and Stock Information - Minichart
VolitionRx (NYSE: VNRX) wins approval for major share issue and reverse split - Stock Titan
Earnings call transcript: VolitionRx Q4 2025 reveals mixed financial results By Investing.com - Investing.com South Africa
Earnings call transcript: VolitionRx Q4 2025 reveals mixed financial results - Investing.com
VolitionRx Limited Q4 2025 Earnings Call Summary - finance.yahoo.com
VolitionRx : Corporate Presentation April 2026 - marketscreener.com
VNRX|VolitionRX Ltd|Price:0.200|Chg%:-0.00 - TradingKey
VolitionRX's Nu.Q Cancer Reimbursement Decision in Q4 2026 Could Unlock Commercial Licensing Momentum Amid Dilution Risks - Bitget
VolitionRx secures €2M in Belgian government financing By Investing.com - Investing.com South Africa
Volitionrx Ltd earnings beat, revenue fell short of estimates By Investing.com - Investing.com India
Volitionrx Ltd earnings beat, revenue fell short of estimates - Investing.com UK
VolitionRX: Q4 Earnings Snapshot - theheraldreview.com
VolitionRX (VNRX) Rating Maintained as Buy by D. Boral Capital | - GuruFocus
VolitionRx (NYSE: VNRX) details going concern risk, funding needs and Nu.Q® rollout - Stock Titan
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update - finance.yahoo.com
VolitionRX Price Target Maintained With a $3.00/Share by D. Boral Capital - Moomoo
VolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Belgian agencies give VolitionRx €2M to advance tests for poorer countries - Stock Titan
VolitionRx biomarkers show elevation in trauma patients study By Investing.com - Investing.com South Africa
VolitionRx biomarkers show elevation in trauma patients study - Investing.com
A blood test before lung surgery helped flag higher-risk patients - stocktitan.net
VolitionRx to outline 2025 results and milestones on April 1 - Stock Titan
VolitionRx Limited (VNRX) Stock: Rallies on Promising Multi-Cancer Early Detection Breakthrough - parameter.io
Blood test detects 95% of stage I and II cancers in blinded study - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
VNRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VolitionRx (NYSE: VNRX) CCO shares withheld and cancelled for RSU taxes - Stock Titan
Tax withholding reduces VolitionRx (NYSE: VNRX) secretary’s share count - Stock Titan
VolitionRx (VNRX) CSO uses 5,310 shares to cover tax bill - Stock Titan
VolitionRx (VNRX) GC has 7,003 shares cancelled for tax withholding - Stock Titan
In today's session, these stocks are experiencing unusual volume. - ChartMill
VNRX Receives Unchanged 'Buy' Rating from D. Boral Capital | VNR - GuruFocus
VolitionRX Ltd (VNRX) Stock Price, Quote, News & History - Benzinga
VolitionRx Limited (VNRX) Stock: Jumps on World-First Cancer DNA Isolation Breakthrough - parameter.io
These stocks are the most active in today's session - ChartMill
Stock Market Volume Leaders: Nasdaq, NYSE, and NYSE American Trading ActivityNews and Statistics - IndexBox
Aug Drivers: What is the cash position of VolitionRx Limited2026 Biggest Moves & High Accuracy Swing Trade Signals - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
VolitionRx (VNRX) Stock Soars 70% on Revolutionary Cancer DNA Discovery - Blockonomi
VolitionRx (VNRX) Stock Soars 70% on Liquid Biopsy Breakthrough - parameter.io
VolitionRx (VNRX) Stock Soars 70% on Revolutionary Cancer DNA Detection Method - MoneyCheck
Finanzdaten der VolitionRX Ltd-Aktie (VNRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
VolitionRX Ltd-Aktie (VNRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Reynolds Cameron John | President and CEO |
Oct 14 '25 |
Buy |
0.51 |
110,000 |
56,100 |
2,534,847 |
| Innes Guy Archibald | Director |
Oct 14 '25 |
Buy |
0.51 |
96,153 |
49,038 |
1,062,967 |
| STILL TIMOTHY I | Director |
Oct 14 '25 |
Buy |
0.51 |
48,076 |
24,519 |
1,535,458 |
| Reynolds Cameron John | President and CEO |
Sep 12 '25 |
Buy |
0.66 |
15,000 |
9,885 |
2,624,847 |
| Innes Guy Archibald | Director |
Aug 05 '25 |
Buy |
0.64 |
78,125 |
50,000 |
966,814 |
| Reynolds Cameron John | President and CEO |
Aug 05 '25 |
Buy |
0.64 |
78,125 |
50,000 |
2,609,847 |
| Reynolds Cameron John | President and CEO |
Jun 12 '25 |
Buy |
0.59 |
12,500 |
7,372 |
2,331,722 |
| Innes Guy Archibald | Director |
Jun 03 '25 |
Buy |
0.54 |
20,000 |
10,772 |
888,689 |
| Micallef Jacob Vincent | Chief Scientific Officer |
May 19 '25 |
Buy |
0.43 |
50,000 |
21,500 |
426,033 |
| Reynolds Cameron John | President and CEO |
May 19 '25 |
Buy |
0.44 |
20,000 |
8,730 |
2,319,222 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):